Quarterly ResultMay 18, 2026, 08:37 AM
Silexion Gets Israel Approval for SIL204 Phase 2/3 Trial; Q1 Net Loss $2.7M
AI Summary
Silexion Therapeutics announced its first quarter 2026 financial results and provided a business update. The company received approval from the Israeli Ministry of Health to initiate its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer and subsequently submitted a Clinical Trial Application to Germany. Financially, Silexion reported a net loss of $2.7 million for Q1 2026, an increase from the prior year, driven by higher R&D and G&A expenses related to clinical trial preparations. The company also undertook capital-raising actions to support its clinical development and maintain Nasdaq listing compliance.
Key Highlights
- Israeli Ministry of Health approved initiation of Phase 2/3 clinical trial for SIL204 in pancreatic cancer.
- Clinical Trial Application for SIL204 Phase 2/3 trial submitted to Germany through EU CTIS.
- Phase 2/3 clinical trial initiation remains on track for the second quarter of 2026.
- Net loss for Q1 2026 was $2.7 million, an increase of 58.8% from Q1 2025.
- Research and development expenses increased 133.3% to $1.4 million in Q1 2026.
- General and administrative expenses rose 27.3% to $1.4 million in Q1 2026.
- Cash and cash equivalents were $2.4 million as of March 31, 2026, down from $6.0 million.
- Shareholders' equity increased above $2.5 million minimum for Nasdaq listing compliance.
Price Impact
More from SLXN